Q-omics provides the consensus-scored NEDD8 profile across patient tissues and cancer cell-line models. NEDD8 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, NEDD8 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NEDD8 RNA expression shows 19,254 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where NEDD8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NEDD8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NEDD8 survival associations across molecular data types. NEDD8 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NEDD8 RNA expression–survival associations across cancer types. High NEDD8 expression shows unfavorable associations in HNSC, UVM, KICH, ACC, LIHC and BLCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for NEDD8 RNA expression.
This table summarizes NEDD8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for NEDD8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NEDD8 shows lower tumor expression in KICH and higher tumor expression in HNSC, BLCA, LIHC, BRCA and CHOL. The HNSC box plot shows higher NEDD8 RNA expression in tumor versus normal tissue (log2 FC = +0.916, t-test p < 0.001).
This table shows molecular features associated with NEDD8 in patient tissues and cancer cell lines. In patient samples, NEDD8 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NEDD8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SKIN.
